drugset
drugset / Trial / NCT07830342

A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer

NCT07830342 ↗

Phase 1 Recruiting 24 enrolled Hangzhou Huasai Biomedicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanced Non-Small Cell Lung Cancer.

Timeline

Start
2026-09-21
Primary completion
2028-10
Completion
2028-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-IT101 Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule — Intravenous
Background aldesleukin Protein / enzyme biologic — Subcutaneous

Indications

non-small cell lung carcinoma